PHASE I STUDY OF ORAL BCX 34 IN PATIENTS W/ T CELL MALIGNANCIES

口服 BCX 34 在 T 细胞恶性肿瘤患者中的 I 期研究

• 批准号: 6264568
• 负责人: JOHN ZIC
• 金额: $ 0.06万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264568
• 关键词: T lymphocyte; antineoplastics; clinical research; clinical trial phase I; human subject; human therapy evaluation; lymphoma; neoplasm /cancer chemotherapy; oral administration

Determine the toxicity produced by the oral administration of BCX-34 administered orally to patients who have T-cell malignancies which have failed light therapy or chemotherapy. We hypothesize that the development and use of VCX-34 will suppress the activity of mammalian purine nucleoside phosphorylase (PNP) which is directly involved in the proliferation of human T-cells.

确定通过口服给药BCX-34对患有光疗法或化疗失败的T细胞恶性肿瘤的患者口服给药产生的毒性。 我们假设VCX-34的开发和使用将抑制哺乳动物嘌呤核苷磷酸化酶（PNP）的活性，该酶直接参与人T细胞的增殖。